Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
103 hedge funds and large institutions have $138M invested in Aratana Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 23 reducing their positions, and 17 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 105 → 103 (-2)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
14% less capital invested
Capital invested by funds: $161M → $138M (-$22.5M)
29% less call options, than puts
Call options by funds: $110K | Put options by funds: $154K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
Engaged Capital
Newport Beach,
California
|
+$8.92M |
| 2 |
Millennium Management
New York
|
+$3.24M |
| 3 |
GAI
General American Investors
New York
|
+$2.23M |
| 4 |
Goldman Sachs
New York
|
+$2.16M |
| 5 |
Renaissance Technologies
New York
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$9.47M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.18M |
| 3 |
AIC
AWM Investment Company
New York
|
-$3.85M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$333K |
| 5 |
EMG
Ellington Management Group
Old Greenwich,
Connecticut
|
-$304K |
PETX Hedge Fund Activity: Q1 2018 in Review
103 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q1 2018, worth a combined $138M — down 14% from $161M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of PETX and 15 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 40 added.
The largest buyer was Engaged Capital, opening a new position worth an estimated $8.92M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $9.47M sold.
- 103 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q1 2018, down from 105 in Q4 2017.
- Funds reported $138M of Aratana Therapeutics, Inc. stock for Q1 2018, down 14% quarter-over-quarter.
- 15 funds opened new Aratana Therapeutics, Inc. positions in Q1 2018 and 17 closed out, a net change of -2 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q1 2018 was Engaged Capital, an estimated $8.92M added.
- The largest Aratana Therapeutics, Inc. seller in Q1 2018 was Janus Henderson Group, an estimated $9.47M sold.
Based on aggregated 13F filings for Q1 2018.